BioSpace News Archive

The following quote is attributed to Frank Yiannas, Deputy Commissioner for Food Policy and Response:

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company has declared a cash dividend of $0.015 per ordinary share, payable in cash on or about August 17, 2020, to shareholders of record on August 10, 2020.

Revive Therapeutics Ltd. is pleased to announce that the U.S. Food & Drug Administration has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Continuous glucose monitoring tracks glucose levels of people with type I or type II diabetes through a device that monitors levels throughout the day.

Helix, the leading population genomics company, today announced that it has been awarded $33.4 M in funding from the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx) program.

Mesa Biotech, developers of an affordable, easy to use, handheld testing platform for infectious diseases diagnosis, today announced it has been awarded a contract up to $15.4 million from the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) program for its Accula™ SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes at the point of care (POC)

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced that it closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel.

OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that Kunwar Shailubhai, Ph.D., the Company’s CEO, will share insight into OKYO’s development pipeline and upcoming milestones during an investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020.

Quidel Corporation announced that Quidel has entered into a preliminary letter contract with the National Institutes of Health through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative to support the expansion of its manufacturing capacity in San Diego for its diagnostic assays that test for SARS-CoV-2 Antigen using its Sofia® Fluorescence Immunoassay platform.

OraSure Technologies, Inc. (NASDAQ: OSUR), today announced that its OMNIgene®·ORAL (OM-505) saliva collection device is included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the United States, for SARS-CoV-2 testing.